Most Recent
Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer's blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.
Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.
Generic drug company Apotex has settled a patent infringement case brought by global pharmaceutical giant Lundbeck over its blockbuster antidepressant Lexapro.
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
The battle over competing shareholder class actions against failed sandalwood oil producer Quintis is heating up, with law firm Gadens launching a bid to shut down the case brought by Bannister Law, attacking its rival's experience and resources.
HarperCollins has lost its bid for summary dismissal of a defamation lawsuit brought against it by two psychiatrists at the centre of the deep sleep therapy scandal that rocked the medical world in the 1960s and 70s.
Macmahon Holdings has agreed to pay $6.7 million to settle a shareholder class action alleging the mining company failed to provide adequate disclosures about the impact delays on a project for Rio Tinto in the Pilbara would have on its profitability.
A Federal Court judge has expressed her disbelief at a cross claim by generic drug maker Sandoz against Danish multinational H Lundbeck, as the court begins to weigh arguments over damages owed to Lundbeck in the long-running patent case over its blockbuster anti-depressant Lexapro.
HarperCollins has asked the Federal Court to toss a defamation case brought against it by two psychiatrists at the centre of the deep sleep therapy scandal that rocked the medical world in the 1960s and 70s, saying too much time had passed since the scandal.
Facing the possibility of more class actions related its use of allegedly toxic firefighting foam at military bases throughout Australia, the Commonwealth has turned to one of the country's largest firms for its defence in the two most recently filed cases.